Shanghai Shen Lian Biomedical Corp (688098) - Net Assets
Based on the latest financial reports, Shanghai Shen Lian Biomedical Corp (688098) has net assets worth CN¥1.42 Billion CNY (≈ $207.93 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.56 Billion ≈ $228.33 Million USD) and total liabilities (CN¥139.42 Million ≈ $20.40 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 688098 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.42 Billion |
| % of Total Assets | 91.06% |
| Annual Growth Rate | 14.3% |
| 5-Year Change | 2.1% |
| 10-Year Change | 349.14% |
| Growth Volatility | 24.71 |
Shanghai Shen Lian Biomedical Corp - Net Assets Trend (2013–2024)
This chart illustrates how Shanghai Shen Lian Biomedical Corp's net assets have evolved over time, based on quarterly financial data. Also explore 688098 total assets for the complete picture of this company's asset base.
Annual Net Assets for Shanghai Shen Lian Biomedical Corp (2013–2024)
The table below shows the annual net assets of Shanghai Shen Lian Biomedical Corp from 2013 to 2024. For live valuation and market cap data, see 688098 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.43 Billion ≈ $208.61 Million |
-5.40% |
| 2023-12-31 | CN¥1.51 Billion ≈ $220.53 Million |
+0.68% |
| 2022-12-31 | CN¥1.50 Billion ≈ $219.04 Million |
+1.62% |
| 2021-12-31 | CN¥1.47 Billion ≈ $215.54 Million |
+5.49% |
| 2020-12-31 | CN¥1.40 Billion ≈ $204.32 Million |
+8.97% |
| 2019-12-31 | CN¥1.28 Billion ≈ $187.49 Million |
+54.01% |
| 2018-12-31 | CN¥831.94 Million ≈ $121.74 Million |
+51.46% |
| 2017-12-31 | CN¥549.27 Million ≈ $80.38 Million |
+18.00% |
| 2016-12-31 | CN¥465.47 Million ≈ $68.11 Million |
+46.65% |
| 2015-12-31 | CN¥317.41 Million ≈ $46.45 Million |
+31.40% |
| 2014-12-31 | CN¥241.57 Million ≈ $35.35 Million |
-26.26% |
| 2013-12-31 | CN¥327.59 Million ≈ $47.94 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Shen Lian Biomedical Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 67.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥404.72 Million | 28.68% |
| Common Stock | CN¥410.64 Million | 29.10% |
| Other Comprehensive Income | CN¥85.52 Million | 6.06% |
| Other Components | CN¥510.41 Million | 36.17% |
| Total Equity | CN¥1.41 Billion | 100.00% |
Shanghai Shen Lian Biomedical Corp Competitors by Market Cap
The table below lists competitors of Shanghai Shen Lian Biomedical Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hubei Sanxia New Building Materials Co Ltd
SHG:600293
|
$543.25 Million |
|
Octopus Apollo VCT PLC
LSE:OAP3
|
$543.26 Million |
|
Martinrea International Inc.
TO:MRE
|
$543.39 Million |
|
Tianjin Pengling Rubber Hose Co Ltd
SHE:300375
|
$543.64 Million |
|
Cytek Biosciences Inc
NASDAQ:CTKB
|
$542.48 Million |
|
Hangzhou Guotai Environmental Protection Technology Co. Ltd. A
SHE:301203
|
$542.48 Million |
|
Vinci Partners Investments Ltd
NASDAQ:VINP
|
$542.42 Million |
|
Chrysos Corporation Ltd
AU:C79
|
$542.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Shen Lian Biomedical Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,488,732,219 to 1,411,295,212, a change of -77,437,007 (-5.2%).
- Net loss of 44,740,058 reduced equity.
- Dividend payments of 14,347,206 reduced retained earnings.
- Share repurchases of 18,324,408 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-44.74 Million | -3.17% |
| Dividends Paid | CN¥14.35 Million | -1.02% |
| Share Repurchases | CN¥18.32 Million | -1.3% |
| Other Changes | CN¥-25.34K | -0.0% |
| Total Change | CN¥- | -5.20% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Shen Lian Biomedical Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.65x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 2.38x to 2.65x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥3.80 | CN¥9.04 | x |
| 2014-12-31 | CN¥2.80 | CN¥9.04 | x |
| 2015-12-31 | CN¥3.68 | CN¥9.04 | x |
| 2016-12-31 | CN¥4.70 | CN¥9.04 | x |
| 2017-12-31 | CN¥1.67 | CN¥9.04 | x |
| 2018-12-31 | CN¥2.47 | CN¥9.04 | x |
| 2019-12-31 | CN¥3.13 | CN¥9.04 | x |
| 2020-12-31 | CN¥3.34 | CN¥9.04 | x |
| 2021-12-31 | CN¥3.60 | CN¥9.04 | x |
| 2022-12-31 | CN¥3.65 | CN¥9.04 | x |
| 2023-12-31 | CN¥3.78 | CN¥9.04 | x |
| 2024-12-31 | CN¥3.41 | CN¥9.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Shen Lian Biomedical Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.17%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14.75%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.10x
- Recent ROE (-3.17%) is below the historical average (11.01%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 12.77% | 21.66% | 0.36x | 1.62x | CN¥9.06 Million |
| 2014 | 25.31% | 30.02% | 0.39x | 2.19x | CN¥36.98 Million |
| 2015 | 23.89% | 31.48% | 0.49x | 1.54x | CN¥44.10 Million |
| 2016 | 15.78% | 27.45% | 0.44x | 1.31x | CN¥26.92 Million |
| 2017 | 17.97% | 32.67% | 0.44x | 1.26x | CN¥43.75 Million |
| 2018 | 10.53% | 31.83% | 0.27x | 1.22x | CN¥4.39 Million |
| 2019 | 6.08% | 30.71% | 0.18x | 1.13x | CN¥-50.17 Million |
| 2020 | 9.27% | 38.35% | 0.22x | 1.08x | CN¥-10.13 Million |
| 2021 | 7.45% | 30.75% | 0.22x | 1.08x | CN¥-37.69 Million |
| 2022 | 4.08% | 18.59% | 0.20x | 1.07x | CN¥-88.59 Million |
| 2023 | 2.12% | 10.45% | 0.19x | 1.07x | CN¥-117.35 Million |
| 2024 | -3.17% | -14.75% | 0.20x | 1.10x | CN¥-185.87 Million |
Industry Comparison
This section compares Shanghai Shen Lian Biomedical Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $6,387,359,426
- Average return on equity (ROE) among peers: 2.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Shen Lian Biomedical Corp (688098) | CN¥1.42 Billion | 12.77% | 0.10x | $543.21 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $948.24 Million | -53.63% | 0.17x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $7.92 Billion | 9.41% | 0.17x | $1.63 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $304.67 Million | -9.25% | 1.53x | $444.78 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $1.06 Billion | 8.06% | 0.08x | $444.44 Million |
| Chengzhi Shareholding Co Ltd (000990) | $15.52 Billion | 0.71% | 0.30x | $2.24 Billion |
| Hualan Biological EngineeringInc (002007) | $6.88 Billion | 18.64% | 0.10x | $3.87 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $428.60 Million | 11.05% | 0.37x | $1.25 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $29.65 Billion | 6.00% | 0.08x | $5.41 Billion |
| Baolingbao Biology Co Ltd (002286) | $703.11 Million | 6.09% | 0.47x | $568.58 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $1.91 Billion |
About Shanghai Shen Lian Biomedical Corp
Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sale of veterinary biological products in China. It develops synthetic peptide vaccines to treat foot-and-mouth diseases. The company was founded in 2001 and is headquartered in Shanghai, China.